Compounding rules and research-supply catalogs are different legal stories

Two commercial stories get collapsed into “you can still get the peptide.” They are not the same story.

Compounding

Under sections 503A and 503B of the Food, Drug, and Cosmetic Act, compounding is a limited exception to ordinary drug approval, with conditions. Bulk substances used for compounding are not an open list. FDA publishes categories and has said that certain nominated substances may present significant safety risks. Peptides have been moved on and off those discussions. The list you remember from a forum post is probably stale. The FDA compounding pages linked here are the ones to check, because this paragraph will not track every category change.

Research-supply catalogs

A separate market sells peptides as research materials, not as compounded prescriptions. NuLife Peptides is one such storefront. Its catalog is a commercial listing of research-supply products. It is not an FDA approval, not a 503A pharmacy, and not evidence that a paper’s results apply to a given lot. This article links one product page, Tesamorelin (10 mg), so the genre is concrete. The link is not an endorsement, and the rest of this journal does not use the catalog as a closing argument.

What the journal will keep doing

We will summarize papers and point at agency documents. We will not pretend a regulatory gray area is a scientific result. If a substance is later approved, the label replaces this commentary. If a listing changes, the storefront is the storefront’s problem to update, not ours to shop from.